LDL receptor related protein 10Genealiases: LRP-10 · LRP9 · MST087 · MSTP087
Q-omics provides the consensus-scored LRP10 profile across patient tissues and cancer cell-line models. LRP10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LRP10 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LRP10 RNA expression shows 19,748 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRC, and ACC as cancer lineages where LRP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRP10 survival associations across molecular data types. LRP10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRP10 RNA expression–survival associations across cancer types. High LRP10 expression shows unfavorable associations in LUAD, LAML, LUSC, LIHC and ACC, but favorable associations in BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LRP10 RNA expression.
This table summarizes LRP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRP10 shows lower tumor expression in KIRC, KICH, COAD and LUSC and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher LRP10 RNA expression in normal versus tumor tissue (log2 FC = −0.741, t-test p < 0.001).
This table shows molecular features associated with LRP10 in patient tissues and cancer cell lines. In patient samples, LRP10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRP10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
